Search results for "Disease management"

showing 10 items of 168 documents

Management of Graves‘Thyroidal And Extrathyroidal Disease – An Update

2020

Abstract Context Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO). Evidence acquisition Guidelines, pertinent original articles, systemic reviews, and meta-analyses. Evidence synthesis Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistent…

MalePediatricsendocrine system diseasesdiagnosisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGraves' diseaseClinical Biochemistryradioactive iodineThyroid GlandBiochemistryHyperthyroidismIodine Radioisotopes0302 clinical medicineEndocrinologyPregnancyUltrasonographytreatmentDisease ManagementReceptors ThyrotropinMini-ReviewGraves Disease030220 oncology & carcinogenesisthyroidectomyBiomarker (medicine)antithyroid drugsFemaleAcademicSubjects/MED00250managementmedicine.drugImmunoglobulins Thyroid-Stimulatingmedicine.medical_specialtyendocrine system030209 endocrinology & metabolismContext (language use)TSH receptor antibodiesDiagnosis Differential03 medical and health sciencesAntithyroid AgentsInternal medicinemedicineHumansRisk factorPregnancyMethimazolebusiness.industryBiochemistry (medical)Thyroidectomymedicine.diseaseGraves OphthalmopathyPregnancy ComplicationsEndocrinologyPropylthiouracilDifferential diagnosisbusinessGraves’ diseaseBiomarkersThe Journal of Clinical Endocrinology and Metabolism
researchProduct

Ketogenic diet for infants with epilepsy: A literature review.

2020

Abstract The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0–23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0–23 months, and we considered only articles published between …

MalePediatricsmedicine.medical_specialtyDrug Resistant EpilepsyKetogenicmedicine.medical_treatmentDrug-resistant epilepsyDrug-resistant epilepsy Epilepsy Glucose transporter type 1 deficiency Infant Ketogenic diet Diet Ketogenic Disease Management Drug Resistant Epilepsy Epilepsy Female Glucose Transporter Type 1 Humans Infant. Infant Newborn. Male Seizures Treatment OutcomeNeonatal ageNewborn. MaleAge limitlaw.invention03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineRandomized controlled triallawSeizuresmedicineGlucose transporter type 1 deficiencyHumans030212 general & internal medicineProspective cohort studyGlucose Transporter Type 1Epilepsybusiness.industryInfant NewbornDisease ManagementInfantRetrospective cohort studyKetogenic dietInfant. InfantDrug Resistant Epilepsymedicine.diseaseDietTreatment OutcomeNeurologyFemaleNeurology (clinical)businessDiet Ketogenic030217 neurology & neurosurgeryKetogenic dietEpilepsybehavior : EB
researchProduct

GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study

2017

Abstract Introduction The 2017 update to the Global Initiative for Obstructive Lung Disease (GOLD) strategy document includes recommendations for treatment intensification or step-down in chronic obstructive pulmonary disease (COPD), although recognises that limited supporting information is available. DACCORD is an ongoing observational, non-interventional study, recruiting patients following COPD maintenance treatment change or initiation, a subset of whom were receiving a long-acting β2-agonist (LABA) plus a long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) on entry. Since there were no requirements in terms of prior medication (and no washout before commencing LABA/L…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationmedicine.drug_classMuscarinic AntagonistsQuinolonesMaintenance ChemotherapyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesGermanyInternal medicineAdministration InhalationmedicineHumansddc:610Longitudinal StudiesProspective Studies030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAgedCOPDbiologybusiness.industryDisease ManagementMiddle AgedLamabiology.organism_classificationmedicine.diseaseGlycopyrrolateObstructive lung diseaseDrug Combinations030228 respiratory systemIndansPractice Guidelines as TopicCritical PathwaysDisease ProgressionPhysical therapyIndacaterolCorticosteroidDrug Therapy CombinationFemaleObservational studybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory Medicine
researchProduct

D-dimer concentrations in acute urticaria in children

2021

Introduction: Urticaria is a clinical entity presenting as wheals, angioedema, or both simul-taneously. Elevated D-dimer levels were reported in the course of chronic spontaneous urticaria. Data regarding D-dimer levels in acute urticaria in children are limited. Objectives: To assess potential associations between duration of glucocorticosteroid (GCS) therapy and D-dimer concentrations in children with acute urticaria. Patients, materials, and methods: Hospital records of 106 children (59 females), aged 5.57 ± 4.91 years, hospitalized in 2014–2018 were analyzed retrospectively. The study group consisted of pediatric patients admitted to the hospital due to severe acute urticaria resistant …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtypediatricsAdolescentUrticariaImmunologyD-dimersglucocorticosteroidsFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinechildrenAmbulatory careInternal medicineWhite blood cellD-dimerHumansImmunology and AllergyMedicinePlateletIn patientacute urticariaChildGlucocorticoidsRetrospective StudiesAcute urticariaAngioedemabusiness.industryDisease ManagementInfantGeneral Medicinemedicine.anatomical_structure030228 respiratory systemChild PreschoolAcute DiseaseAntihistaminic drugsFemalemedicine.symptombusinessBiomarkers030215 immunologyAllergologia et Immunopathologia
researchProduct

Characteristics, Management Techniques, and Outcomes of the Most Common Soft-Tissue Hand Tumors: A Literature Review and Our Experience

2017

INTRODUCTION Diagnosis of the hand's soft-tissue tumors is often difficult because of the different anatomic structures present in this region and yet clinicians must be able to distinguish typical benign entities from life-threatening or limb-threatening malignant diseases. MATERIALS AND METHODS At the Department of Plastic and Reconstructive Surgery at the University of Palermo, 629 patients with hand tumors were studied. Treatment was surgical for all of them; also radiotherapy and chemotherapy were necessary based on the histological diagnosis. CONCLUSIONS Our retrospective study with a literature review aims to present the most commonly observed soft-tissue hand lesions, analyzing thei…

MaleReconstructive surgerymedicine.medical_specialtySoft Tissue NeoplasmSkin Neoplasmssurgical excisionPrognosimedicine.medical_treatmentTreatment outcomeSoft Tissue Neoplasms030230 surgeryRisk Assessment03 medical and health sciences0302 clinical medicineInstrumental evaluationRetrospective StudieHistological diagnosismedicineHumansReconstructive Surgical ProcedureSkin NeoplasmSoft Tissue NeoplasmRetrospective Studieshand tumorbusiness.industryGeneral surgeryIncidenceSoft tissueDisease ManagementRetrospective cohort studyPlastic Surgery ProceduresPrognosisHandSurgeryRadiation therapyTreatment Outcomesoft-tissue lesionItaly030220 oncology & carcinogenesisSurgeryFemalebusinessHuman
researchProduct

Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics

2018

International audience; Importance - The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. Objective - To determine the clinical outcomes of patients with asymptomatic AS using data from the Heart Valve Clinic International Database. Design, setting, and participants - This registry was assembled by merging data from prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada, and the United States. Asymptomatic patients with an aortic valve area of 1.5 cm2 or less and preserved left ventricular ejection fraction (LVEF) greater than 50% at entry were considered for the prese…

MaleRegistrieUnited StateCanadamedicine.medical_specialty030204 cardiovascular system & hematologyAsymptomaticSudden deathDisease-Free Survival03 medical and health sciences0302 clinical medicineAortic valve replacementRetrospective StudieInternal medicinemedicineHumansProspective StudiesRegistries030212 general & internal medicineHeart valveWatchful WaitingProspective cohort studyRetrospective StudiesAgedAged 80 and overAsymptomatic DiseaseEjection fractionbusiness.industryDisease ManagementAortic Valve StenosisMiddle Agedmedicine.diseaseAortic Valve StenosiUnited States3. Good healthEuropeProspective StudieStenosisDeath Sudden Cardiacmedicine.anatomical_structureAortic valve stenosisAsymptomatic DiseasesCardiology[SDV.IB]Life Sciences [q-bio]/BioengineeringFemalemedicine.symptombusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).

2020

Abstract Aims Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb3). Patients with amenable GLA mutations can be treated with migalastat, an oral pharmacological chaperone increasing endogenous AGAL activity. In this prospective observational multicentre study, safety as well as cardiovascular, renal, and patient-reported outcomes and disease biomarkers were assessed after 12 and 24 months of migalastat treatment under ‘real-world’ conditions. Methods and results A total of 54 patients (26 females) (33 of these [61.1%] pre-treated with en…

Malemedicine.medical_specialty1-DeoxynojirimycinGlobotriaosylceramideRenal functionDiseaseGastroenterology03 medical and health scienceschemistry.chemical_compoundInternal medicineMigalastatmedicineHumansPharmacology (medical)Prospective Studies030304 developmental biology0303 health sciencesbusiness.industry030305 genetics & heredityDisease ManagementEnzyme replacement therapymedicine.diseaseFabry diseaseMulticenter studychemistryFabry DiseaseObservational studyFemaleCardiology and Cardiovascular MedicinebusinessEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

Prognosis and Management of Acute Coronary Syndrome in Spain in 2012: The DIOCLES Study

2015

Abstract Introduction and objectives To identify the current mortality and management of patients admitted for suspected acute coronary syndrome in Spain. The last available registry (2004-2005) reported an in-hospital mortality of 5.7%. Methods The study included patients consecutively admitted between January and June 2012 at 44 hospitals selected at random. Information was collected on clinical course at admission and on events at 6 months. Results A total of 2557 patients admitted with suspected acute coronary syndrome were included: 788 (30.8%) with ST-segment elevation, 1602 (62.7%) without ST-segment elevation, and 167 (6.5%) with unclassified acute coronary syndrome. In-hospital mor…

Malemedicine.medical_specialtyAcute coronary syndromePercutaneousmedicine.medical_treatmentCoronary AngiographyBalloon inflationElectrocardiographyInternal medicinemedicineHumansHospital MortalityRegistriesAcute Coronary SyndromeAgedRetrospective StudiesAged 80 and overManagement of acute coronary syndromebusiness.industryIncidenceClinical courseDisease ManagementPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle AgedPrognosismedicine.diseaseFrequent useHospitalizationCross-Sectional StudiesSpainCardiologyFemalebusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and S…

2019

ABSTRACT Nowadays, the intensive cardiac care unit (ICCU) provides care for patients with acute coronary syndrome, acute and exacerbated chronic heart failure, cardiogenic shock, sudden cardiac arrest, electrical storm, as well as with indications for urgent cardiac surgical treatment. Most of these patients require the use of 1, 2, or frequently even 3 drugs that act on the blood coagulation pathway. While antithrombotic drugs prevent thromboembolic events, they are associated with a higher risk of bleeding. In this population of patients, bleeding may often have a worse impact on prognosis than the primary disease. In this expert opinion of the Association of Intensive Cardiac Care, we pr…

Malemedicine.medical_specialtyAcute coronary syndromePopulationCardiologyHemorrhagePharmacotherapyFibrinolytic AgentsRisk FactorsThromboembolismAntithromboticmedicineHumansIn patientCardiac Surgical ProceduresIntensive care medicineeducationSocieties MedicalAgedAged 80 and overeducation.field_of_studybusiness.industryCardiogenic shockDisease ManagementSudden cardiac arrestmedicine.diseaseIntensive Care UnitsHeart failureFemalePolandmedicine.symptomCardiology and Cardiovascular MedicinebusinessKardiologia polska
researchProduct